Countless studies showed that fullerene (C60) and derivatives could have many potential biomedical applications. However, while several independent research groups showed that C60 has no acute or subacute toxicity in various experimental models, more than 25 years after its discovery the in vivo fate and the chronic effects of this fullerene remain unknown. If the potential of C60 and derivatives in the biomedical field have to be fulfilled these issues must be addressed. Here we show that oral administration of C60 dissolved in olive oil (0.8 mg/ml) at reiterated doses (1.7 mg/kg of body weight) to rats not only does not entail chronic toxicity but it almost doubles their lifespan. The effects of C60-olive oil solutions in an experimental model of CCl4 intoxication in rat strongly suggest that the effect on lifespan is mainly due to the attenuation of age-associated increases in oxidative stress. Pharmacokinetic studies show that dissolved C60 is absorbed by the gastro-intestinal tract and eliminated in a few tens of hours. These results of importance in the fields of medicine and toxicology should open the way for the many possible -and waited for- biomedical applications of C60 including cancer therapy, neurodegenerative disorders, and ageing.
The study involved about 60 rats. Six sets of ten rat groups. The weight of the treated rats did not go down so it would suggest they did not severely calorie restrict the rats, although there could have been some intermittent fasting.
The results of this pharmacokinetic study show for the first time that C60 is absorbed by the gastro-intestinal tract. In the case of oily solutions, the drug release rate is controlled by the partition coefficient of the drug between the oily vehicle and the tissue fluid and lipophilic drugs may be released concurrently with the disappearance of the oily vehicle from the injection site.
Four possible mechanisms for C60-liver protection were proposed:
(1) C60 can scavenge large numbers of free radicals
(2) it can act as a decomposition catalyst for O2/H2O2, as it has been postulated for its tris-malonic acid derivatives
(3) as a cytochrome P450 inhibitor as it has been reported for some fullerene derivatives
(4) it can inactivate Kupffer cells (liver resident macrophages) through accumulation and overloading with a large number of C60 aggregates
Pathological examinations show that even at very low doses, 500 times lower than that used previously, C60-olive oil solutions effectively protects the livers against CCl4 toxicity. These results are in agreement with those reported for very low doses of water solution of hydrated C60 fullerene in other experimental models.
The effect of pristine C60 on lifespan emphasizes the absence of chronic toxicity. These results obtained with a small sample of animals with an exploratory protocol ask for a more extensive studies to optimize the intestinal absorption of C60 as well as the different parameters of the administration protocol: dose, posology and treatment duration. In the present case, the treatment was stopped when a control rat died at M17, which proves that the effects of the C60 treatment are long-lasting as the estimated median lifespan for C60-treated rats is 42 months. It can be thought that a longer treatment could have generated even longer lifespans. Anyway, this work should open the road towards the development of the considerable potential of C60 in the biomedical field, including cancer therapy, neurodegenerative disorders and ageing. Furthermore, in the field of ageing, as C60 can be administered orally and as it is now produced in tons, it is no longer necessary to resort to its water-soluble derivatives, which are difficult to purify and in contrast to pristine C60 may be toxic.
Brian Wang is a Futurist Thought Leader and a popular Science blogger with 1 million readers per month. His blog Nextbigfuture.com is ranked #1 Science News Blog. It covers many disruptive technology and trends including Space, Robotics, Artificial Intelligence, Medicine, Anti-aging Biotechnology, and Nanotechnology.
Known for identifying cutting edge technologies, he is currently a Co-Founder of a startup and fundraiser for high potential early-stage companies. He is the Head of Research for Allocations for deep technology investments and an Angel Investor at Space Angels.
A frequent speaker at corporations, he has been a TEDx speaker, a Singularity University speaker and guest at numerous interviews for radio and podcasts. He is open to public speaking and advising engagements.